Sigma-Tau is developing this product as an emergency treatment for severe and complicated malaria in collaboration with the Walter Reed Army Institute of Research.
Gregg Lapointe, Sigma-Tau Pharmaceutical’s COO, said: “We commend the European Commission for granting orphan drug designation to Artesunate. The designation reinforces Sigma-Tau’s commitment to the development of new medicines for neglected diseases.”